Tuberculosis(TB) is an infection caused by Mycobacterium tuberculosis and is one of the world's deadliest diseases. Multidrug resistant TB(MDR-TB) is a serious form of TB and it implies resistance for at least two...Tuberculosis(TB) is an infection caused by Mycobacterium tuberculosis and is one of the world's deadliest diseases. Multidrug resistant TB(MDR-TB) is a serious form of TB and it implies resistance for at least two essential first-line agents like, Isoniazid and Rifampicin. The US Food and Drug Administration(FDA) granted accelerated approval to Janseen Therapeutics "Sirturo(Bedaquiline)", a diarylquinoline anti mycobacterial drug on December 28, 2012 as part of combination therapy in adults(≥ 18 years) to treat MDR-TB when other alternatives are not available. The FDA also granted Sirturo fast track designation, priority review and orphanproduct designation. Bedaquiline inhibits mycobacterial ATP(adenosine 5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.展开更多
文摘Tuberculosis(TB) is an infection caused by Mycobacterium tuberculosis and is one of the world's deadliest diseases. Multidrug resistant TB(MDR-TB) is a serious form of TB and it implies resistance for at least two essential first-line agents like, Isoniazid and Rifampicin. The US Food and Drug Administration(FDA) granted accelerated approval to Janseen Therapeutics "Sirturo(Bedaquiline)", a diarylquinoline anti mycobacterial drug on December 28, 2012 as part of combination therapy in adults(≥ 18 years) to treat MDR-TB when other alternatives are not available. The FDA also granted Sirturo fast track designation, priority review and orphanproduct designation. Bedaquiline inhibits mycobacterial ATP(adenosine 5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.
